# Efficacy, Safety, Tolerability and Pharmacokinetics of KAE609 in Adult Patients With Acute, Uncomplicated Plasmodium Falciparum or Vivax Malaria Mono-infection

> **NCT01524341** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 27 (actual)

## Conditions studied

- Malaria

## Interventions

- **DRUG:** KAE609

## Key facts

- **NCT ID:** NCT01524341
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-01
- **Primary completion:** 2012-06
- **Final completion:** 2012-06
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2013-05-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01524341

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01524341, "Efficacy, Safety, Tolerability and Pharmacokinetics of KAE609 in Adult Patients With Acute, Uncomplicated Plasmodium Falciparum or Vivax Malaria Mono-infection". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01524341. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*